Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-Associated methicillin-resistant staphylococcus aureus bacteremia

The purpose of this study was to compare the clinical efficacy and safety of vancomycin to those of teicoplanin for the treatment of adult patients with health care-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) bacteremia. A multicenter observational study was prospectively conducted in 15 teaching hospitals in Korea between February 2010 and July 2011. Adult patients (≥18 years old) with HA-MRSA bacteremia who were initially treated with vancomycin (VAN) (n=134) or teicoplanin (TEC) (n=56) were enrolled. Clinical and microbiological responses and drug-related adverse events were compared between the two treatment groups using univariate and multivariate logistic regression analyses. The vancomycin and teicoplanin MICs were determined by Etest. The MRSA-related mortality, duration of fever, and duration of MRSA bacteremia in the treatment groups were not significantly different. There was no significant difference in the occurrence of drug-related adverse events.Among the 190 MRSA isolates, the VAN MICs ranged from 0.5 to 2 μg/ml (MIC⁵⁰ and MIC⁹⁰, 1.5 μg/ml), and the TEC MIC ranged from 0.5 to 8 μg/ml (MIC⁵⁰, 3 μg/ml; MIC⁹⁰, 6 μg/ml). In multivariate analyses, the antibiotic type (vancomycin or teicoplanin) was not associated with treatment outcomes. This study indicates that teicoplanin is an effective and safe alternative to vancomycin for the treatment of HA-MRSA bacteremia.